Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study

• Published in: Journal of personalized medicine Vol. 12; no. 5; p. 694
• Main Authors: Vollenberg, Richard, Tepasse, Phil-Robin, Lorentzen, Eva, Nowacki, Tobias Max
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 26.04.2022; MDPI
• Subjects: ACE2; Angiotensin-converting enzyme 2; Antigens; Coronaviruses; COVID-19 vaccines; Crohn's disease; Humoral immunity; Immune response (humoral); Immunoglobulin G; Immunosuppressive agents; Infections; Inflammatory bowel disease; Inflammatory bowel diseases; Infliximab; Lymphocytes T; Monoclonal antibodies; mRNA; mRNA vaccines; Pandemics; Patients; Precision medicine; Proteins; Remission (Medicine); Severe acute respiratory syndrome coronavirus 2; Spike protein; Tumor necrosis factor-α; Vaccines; γ-Interferon; United States > US; Germany; Chicago Illinois; COVID-19; SARS-CoV-2; IBD patients; seroconversion; humoral and T-cellular immune response; vaccination

Introduction: The Coronavirus Disease 2019 (COVID-19) pandemic has been caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The most important approach to prevent severe disease progression and to contain the pandemic is the use of COVID-19 vaccines. The aim of this study was...